This systematic review showed that tocilizumab, sarilumab, and anakinra (IL-1 ra) could reduce the mortality of people with COVID-19 (on the verge of sepsis), and tocilizumab did not significantly affect side and adverse effects and secondary infections [122]. This evidence concerns the gene IL1B and COVID-19.